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Abstract
Specific nucleases (SNs), including ZFNs, TALENs, and CRISPR (clustered regularly
interspaced palindromic repeats), are powerful tools for genome editing (GE). These tools
have achieved efficient gene repair and gene disruption of human primary cells. However,
their efficiency and safety must be improved before translation into clinic. In particular,
one of the main hurdles of GE technology is the delivery of the different components into
the nucleus of target cells. Successful gene editing must be able to deliver the SNs and/or
the donor DNA into a large number of target cells in order to have a therapeutic benefit.
In addition, the delivery must be nontoxic and the SNs must be innocuous to the target
cells. In this chapter, we will summarize the different ways to deliver SNs and donor
DNA.
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1. Introduction
Although genome editing (GE) technologies have been used for more than 30 years, the efficiency
and specificity was too low to be used in gene therapy (GT). However, the development of
specific nucleases (SNs) that can enhance homologous directed recombination (HDR) up to
10,000 times and allows the generation of specific mutations have open new possibilities for the
use of GE for GT applications. SNs can create specific DSBs at target locations in the genome.
These DSBs must be repaired by the cell’s endogenous mechanisms by either HDR, a high-
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fidelity reparation process, or by nonhomologous end joining (NHEJ), an error prone process
that results in insertions or deletions (indels) at the cleavage site. This repair mechanism is used
as a platform for GE. Depending on the mechanism used by the cells to repair the DSBs, we can
repair, insert, or delete DNA fragments in the genome of the target cells. There are four families
of SNs being used: meganucleases (MNs) [1], zinc finger nucleases (ZFNs) [2], transcription
activator-like effectors nucleases (TALENs) [3], and the clustered regularly interspaced short
palindromic repeats (CRISPR) and CRISPR Associated 9 (Cas9) (CRISPR/Cas9) system [4] also
named RNA-guided nulceases (RGNs). MNs, ZFNs, and TALENs used the principles of DNA-
protein recognition to target specific locus. However, the difficulties of protein design, synthesis,
and validation blocked the widespread adoption of these engineered nucleases for routine use
in many laboratories. The field is experiencing a new phase thanks to the development of the
RGNs [4]. This two-component system can achieve specific cleavage in any target DNA location
guided by a small RNA molecule named gRNA [5].
However, in spite of the great advances in SNs design, the translation of GE technologies into
clinic still requires several refinements both in terms of specificity and efficiency [6]. The
efficiency of a particular GE strategy largely relies on the efficiency of delivery of the SNs and/
or the donor DNA. In this chapter, we will discuss the different tools available for the delivery
of the different components required for GE.
2. Viral-based vectors
GE using SNs and/or a donor DNA requires vector systems that efficiently deliver both
components into the target cells. This is a relative easy task for cells that are growing in the
laboratories but is a much difficult task when we target primary human cells. In general, viral-
based vectors are more efficient than non-viral for most primary human cells. Since transient
expression of GE components is preferred over stable expression, we will focus on episomal
(non-integrative) viral-based vectors.
2.1. Adenoassociated virus (AAV)-based vectors
AAVs have been used for the delivery of ZFNs; however, the limited capacity of the AAV
vectors makes difficult the use of these vectors for the delivery of Cas9 and TALEN. The first
report showing the efficacy of AAV vectors to deliver ZFNs was published in 2012 [7, 8]. Soon
later, the group of Katherine High showed that systemic AAV-ZFNs and AAV-corrective
donor template enables production of high levels of human factor IX in a murine model of
hemophilia B [9]. In another study, Weber et al. [10] reported that the administration of AAV-
ZFNs-targeting HBV polymerase achieved an inhibition of HBV replication. In spite of their
big size, several groups have attempted to deliver S. pyogenes Cas9 and its gRNA using AAV
vectors [11]. However, oversized AAV vectors render inconsistent results [12]. As an alterna‐
tive, different groups deliver the gRNA and the Cas9 in separate AAVs with very promising
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results [13]. Indeed, these two-AAV vectors systems have achieved correction of dystrophin
expression in a mouse model of Duchenne muscular dystrophy (DMD) [14] and correction a
metabolic liver disease [15].
Recently, the development of a new RGN based in the smaller Cas9 from S. aureus [16] opened
the possibility of generating AAV vectors harboring both Cas9 and gRNA expression cassettes.
Taking the advantage of this smaller Cas9, several groups have developed “All-In-One” AAV-
RGN systems obtaining very promising results in animal models of DMD [17, 18]. In these
experiments, systemic delivery of AAV-Cas9-gRNA to DMM mice resulted in the expression
of the dystrophin gene with improvements of muscle biochemistry and enhancement of
muscle force.
Beside the potential of AAV as a gene delivery tools, it has been reported that these vectors
are able to enhance up to 1000-fold the HDR rate in mammalian cells [19]. In fact, the delivery
of corrective donor DNA (without SNs) with AAV has achieved correction of mucopolysac‐
charidosis [20] and hereditary tyrosinemia [21] in mouse models. Of course, scientists have
taken advantage of this property and have combined SNs with delivery of Donor DNA by
AAV vectors. Wang and colleagues [22], combined electroporation of ZFN mRNA (see below)
with donor delivery by AAV serotype 6, achieving efficient GE in HSPCs (up to 50% of CCR5
specific insertion) and T cells. Anguela et al. [9] and Sharma et al. [23] showed that systemic
delivery of AAV-ZFNs and AAV-Donor to adult mice can achieve high levels of human factor
VIII and IX in murine models of hemophilia A and B. Recently Yang et al. [15] corrected a
metabolic liver disease using a similar strategy. Using AAV to deliver ZFNs and donor DNA,
Sharma et al. [23] reported a general strategy for liver-directed protein replacement therapies
that allows site-specific integration of therapeutic transgenes within the albumin gene. The
authors achieved long-term expression of human factors VIII and IX as well as lysosomal
enzymes in different animal models of hemophilia, Fabry and Gaucher disease, and Hurler
and Hunter syndrome. An additional property of AAV that make these viruses an ideal tool
for delivery of Donor DNA is it high specificity for the target locus [24]
2.2. Adevovirus (AdV)-based vectors
AdVs are highly attractive for viral delivery of SNs and in particular for TALENs due to their
high cargo capacity, their ability to transduce dividing and nondividing cells and their
transient expression. In addition, similarly to AAV, AdVs started to be used as a tool to deliver
large donor DNA for homology-directed gene-targeting experiments (without the use of SNs).
This approach has been used in order to correct the HPRT in mouse ES cells [25] or LMNA
gene in pluripotent stem cells [26]. Of course, the appearance of SNs prompts scientists to use
AdV not only for delivery of the donor DNA but also for the delivery of SNs. In this context,
one of the major successes was achieved by the expression of ZFNs targeting the CCR5 locus
into CD4+ T cells [27–29]. In fact, AdV delivery of ZFNs was the first GE strategy been approved
for their use in clinical trials. The strategy aimed to knock down CCR5 expression (a co-receptor
for HIV-1 entry into cells) from T cells derived from HIV-1 patients [29]. On the other hand
and taking into account the large cargo capacity of AdVs in comparison with AAV, the AdV
have been used not only for the delivery of TALENs [30] and Cas9/gRNA [31, 32], but also as
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a source of donor DNA templates for homology-directed gene editing after site-specific
chromosomal DSB formation by ZFNs, TALENs, and RGNs. Interestingly, it was found that
protein-capped adenovirus genomes favored a more specific GE by HDR templates compared
to un-capped linear templates. However, the strong immune response elicited by these viruses
may limit their potential in clinical settings [33]
2.3. Lentiviral vectors (LVs) and integration-deficient lentiviral vectors (IDLVs)
LVs have been successfully used for efficient transduction of the most cell types, including
hard to transfect primary differentiated cells (such as neurons, T cells, or macrophages) as well
as multipotent (MSCs, HSCs) and pluripotent stem cells (hESCs and iPSCs). Due to the high
efficiency of LVs, scientists have used this platform also for the transient delivery of transgenes
by mutating the integrase protein and develop IDLVs [34]. The development of IDLVs opened
the possibility of using these systems for GE in therapeutic settings. IDLVs have been used to
deliver cDNAs expressing ZFNs, TALENs, and RGNs. However, only ZFNs genes have been
delivered with high efficiency using these systems [24, 35–37]. In one of the first demonstration
of IDLVs efficacy for GE, Lombardo et al. [35] showed that IDLV delivery of ZFNs can achieve
high levels of gene addition (over 50%) in several primary human cell lines, including
hematopoietic stem cells. IDLVs have also been very successful for GE of T cells [38, 39].
Delivery of RGNs and TALENs by IDLVs has been more challenging due to the larger size of
Cas9 and the high recombination rates of TALENs [40]. Some authors have developed LVs
with mutated reverse transcriptase to deliver mRNA avoiding recombination. Using this
system, the authors showed efficient CCR5 and TCR gene suppression in different cell lines
[41].
IDLVs have also been adapted for the delivery of SNs proteins instead of delivery of cDNA,
providing efficient targeted gene disruption in several primary cells [42]. By co-packaging
ZFNs or TALENs proteins and donor RNA in lentiviral particles, the authors achieved
homology-directed DNA insertion and gene correction.
The ability to deliver circular DNAs into the nuclei of target cells, including quiescent cells,
make IDLVs a very interesting tool to deliver donor DNAs [35–37]. Compared with AAV and
AdV, IDLVs have the advantage of enhanced efficiency in some target cells, such as hemato‐
poietic stem cells (HSCs), a very interesting target population for GT strategies. Using IDLVs
to deliver Donor DNA, Genovese et al. [43] managed to restore up to 6% of CD34+ cells from
a SCID-X1 patient. The main advantage of using IDLVs for delivery of the Donor DNA is the
high efficacy; however, quite often (5–20%) the Donor DNA integrates outside that target locus.
These off-target integrations can have undesired side effect and is something that need to be
monitored in detailed.
3. Non-viral-based vectors
As we have discussed in the previous section, the different viral vectors have different
applications in GE, each one with its own limitation. In this section, we will discuss the best
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non-viral gene transfer technologies that have been developed for ex vivo and in vivo delivery
of GE tools, in particular for the delivery of SNs. These systems have often been combined
with viral-based methods for the delivery of donor DNAs.
3.1. Nucleofection
NucleofectorTM Technology-Lonza, also named nucleofection, is a electroporation-based
system that allows high transfection efficiencies with high cell viability in most cell types
including hHSCs, dentritic cells, and iPS. Nucleofection of SNs in the form of DNA, RNA, and
proteins has been a successful approach for GE of primary human cells. This technique has
been used to achieve therapeutic benefits by NHEJ and by HDR (often combined with viral-
based methods for delivery of the donor DNA).
Examples of mRNA nucleofection for NHEJ-based GT can be found in the clinical trial for
Duchenne muscular dystrophy patients. The protocol resulted in a deletion of a defective
sequence, partially restoring the expression of dystrophin [44]. In a similar strategy, Poirot et
al. [45] nucleofected TALEN mRNA into T cells allowing highly efficient gene disruption of
alphabeta T-cell receptor (TCR) and CD52 (a protein targeted by alemtuzumab). These cells
did not mediate graft versus host reactions and were resistant to alemtuzumab, increasing the
safety and efficacy of CAR T cells immunotherapies [45]. The CCR5 T cell receptor (see above)
was also targeted efficiently by nucleofection of TALEN mRNAs [46]. Recently, a clinical scale
protocol for gene disruption of the PD-1 gene in tumor-infiltrating lymphocytes (TILs) has
been developed [47]. In this protocol, nucleofection of T cells with ZFNs mRNA resulted in
80% reduction in PD-1 surface expression in TILs.
The first experiments showing HDR in primary human cells used nucleofection of plasmids
to deliver both SNs and Donor DNA [48]. The authors showed specific modification (inclusion
of new restriction enzymes) of the IL2Rgamma gene in over 10% of primary human T cells.
However, efficiencies in other target cells remained very low for therapeutic applications.
Different groups have shown that combining mRNA nucleofection with delivery of Donor
DNA by IDLVs [43] or AAV [22] rendered better results due to the ability of the viral vectors
to improved efficiency of HDR.
3.2. Liposomes and cationic polymers
Liposomes and cationic polymers (i.e., polyethylenimine-PEI) allow delivery of large DNA
fragments due to the interactions between the cationic charge of the particles and the anionic
charge of the cell membranes. Cationic liposomes have shown good efficacies for transfection
of DNA expressing ZFNs [27, 48, 49], TALEN [50] and Cas9/gRNAs [50, 51].
In a GT application, HPV-targeted TALEN plasmids were used for in vivo delivery using
TurboFect1 [50], a proprietary cationic polymer (ThermoFisher Scientific). Direct applications
of the TurboFect1-Cas9-gRNA complex into the cervix of transgenic mice displaying HPV
infection and cervical cancer reduced viral loads and tumor size [50]. Other reports have
showed efficient ex vivo and in vivo delivery of Cas9 protein complexes with gRNA using
liposomes [53, 54].
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Some groups have combined the delivery of the CRISPR/Cas as a protein but fusion to a
cationic liposome reagent. Zuri et al. [54] hypothesized that proteins that are highly anionic
could be delivered by the same electrostatics-driven complexation used by the cationic
liposomal reagents. They showed that the Cas9 nuclease protein with the polyanionic single
guide RNA could be delivered efficiently and functional into mammalian cells using this
cationic lipid formulations and at the same time is able to create indels in a efficient way;
approximately 10 folds compared with the plasmid transfection [54]
3.3. SNs proteins and cell-penetrating peptides (CPPs)
It was soon observed that ZFNs have an intrinsic cell-penetrating activity due to the positive
charge of the zinc finger domains [55]. In fact, direct delivery of ZFNs proteins achieved up to
24% gene disruption of CCR5 in HEK and HDF cells and up to 8% in human T cells [55].
However, unlike ZFNs, TALEN are incapable of penetrating cellular membranes [56] and
therefore, cell-penetrating peptides (CPPs) are required to promote cellular uptake. CPPs, also
known as protein transduction domains or membrane translocation sequences, are short
cationic or amphypatic peptides of 5–40 amino acids that can traverse mammalian plasma
membranes [57]. Ru et al. fused TALENs with HIV-1 TAT protein (a CPPs) and showed 3 and
5% of CCR5 gene disruption in HeLa and hiPSC cells, respectively. TALENs have also been
conjugated with poly-Arg9 peptides (R9CPP) [58]. The conjugated R9-TALEN proteins were
able to knockout CCR5 and BMPR1A genes in HeLa and HEK293 cells.
The delivery of the CRIPR/Cas9 system by its fusion with CPPs has also been used in different
cells types, such as fibroblast and pluripotent stem cells. Delivery of the Cas9 and gRNA
conjugated with m9R and 9R CPPs, respectively, resulted in mutation frequencies ranging
from 2.3 to 16% in several human cells including embryonic stem cells [59].
3.4. Nanoparticles
Nanoparticles are particles between 1 and 100 nanometers in size generated by different
strategies such as attrition, pyrolysis, or hydrothermal synthesis. The group of Marie E. Egan
developed a new method for surface-modifying PLGA nanoparticles with cell-penetrating
peptides [60] and then combined to develop PLGA/PBAE/MPG nanoparticles, achieving
modification of 5% of the cells in the nasal epithelium and more than 1% in the lung. Using
this system, the authors deliver PNAs and donor DNA molecules to correct the F508del CFTR
mutation achieving in vitro and in vivo gene correction an order of magnitude higher than
previously achieved [61].
Other strategies combined triplex-forming peptide nucleic acids (PNAs), synthetic oligonu‐
cleotide analogs that are resistant to degradation with nanoparticles [62]. PNAs have also the
advantage that can induce DNA repair upon sequence-specific triplex formation at targeted
genomic sites. The direct delivery of PNAs and Donor DNA by nanoparticles can mediate GE
of human cells at frequencies of 0.05% in HSCs [63]. Other authors used biodegradable poly
(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating PNAs and donor DNAs to
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disrupt CCR5, achieving up to 1% gene disruption in HSCs and conferring HIV-1 resistance
to an humanized mice model [64].
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